MR. WILLIAM JON HANSEN, NP
Nursing in San Francisco, CA
License number
California 8694
Category
Nursing
Type
Adult Health
Address
Address
2238 Geary Blvd 6 WEST, San Francisco, CA 94115
Phone
(415) 833-2831
Personal information
See more information about WILLIAM JON HANSEN at radaris.comName
Address
Phone
521 Banyan Cir, Walnut Creek, CA 94598
5158 Don Mata Dr, Carlsbad, CA 92010
520 Cane St, Larkspur, CA 94939
533 Hamburg Cir, Clayton, CA 94517
5006 Pleasant Dr, Sacramento, CA 95822
Professional information
See more information about WILLIAM JON HANSEN at trustoria.com
Pres./Ceo Hansen Insurance
Pres./Ceo Hansen Insurance
Location:
San Francisco Bay Area
Industry:
Insurance
Skills:
Insurance, Commercial Insurance, Property & Casualty Insurance, Investments, Commercial Lines, Underwriting, Financial Risk
William J Hansen, San Francisco CA - NP (Nurse practitioner)
William J Hansen, San Francisco CA - NP (Nurse practitioner)
Specialties:
Nursing (Nurse Practitioner), Adult Health Nursing (Nurse Practitioner)
Address:
2238 Geary Blvd, San Francisco 94115
(415) 833-2831 (Phone)
(415) 833-2831 (Phone)
Languages:
English
William Jon Hansen, San Francisco CA
William Jon Hansen, San Francisco CA
Specialties:
Nurse Practitioner
Address:
2238 Geary Blvd, San Francisco, CA 94115
Diamino-Phenothiazinyl Derivatives As Antiviral Treatments
Diamino-Phenothiazinyl Derivatives As Antiviral Treatments
US Patent:
8227459, Jul 24, 2012
Filed:
Apr 3, 2008
Appl. No.:
12/062491
Inventors:
Jacob Plattner - Berkeley CA, US
Colm Kelleher - Lafayette CA, US
Vishwanath Lingappa - San Francisco CA, US
Beverly Freeman - Albany CA, US
William Hansen - San Francisco CA, US
Colm Kelleher - Lafayette CA, US
Vishwanath Lingappa - San Francisco CA, US
Beverly Freeman - Albany CA, US
William Hansen - San Francisco CA, US
Assignee:
Prosetta Antiviral Inc. - San Francisco CA
International Classification:
A61K 31/54
US Classification:
5142248
Abstract:
Compounds and methods for preventing and treating viral infections are provided. In some embodiments, novel compounds broad-spectrum antiviral activity are provided. In more specific embodiments, the compounds and methods are effective against viruses such as Venezuelan Equine Encephalitis, West Nile Virus, and Hepatitis C.
Conformer-Specific Antibodies And Method Of Use, Thereof
Conformer-Specific Antibodies And Method Of Use, Thereof
US Patent:
2007001, Jan 18, 2007
Filed:
Jun 22, 2006
Appl. No.:
11/473460
Inventors:
Vishwanath Lingappa - San Francisco CA, US
Mahadevappa Prasad - San Francisco CA, US
William Hansen - San Francisco CA, US
Joshua Lehrer-Graiwer - San Francisco CA, US
Carsten Korth - Dusseldorf, DE
Mahadevappa Prasad - San Francisco CA, US
William Hansen - San Francisco CA, US
Joshua Lehrer-Graiwer - San Francisco CA, US
Carsten Korth - Dusseldorf, DE
International Classification:
G01N 33/53, C07H 21/04, C12P 21/06, C12N 5/06, C07K 16/18
US Classification:
435007100, 435069100, 435320100, 435326000, 530387100, 536023530
Abstract:
A number of polypeptides exist in different three-dimensional conformations, or “conformers,” which have different biological functions despite having the same or substantially the same primary polypeptide sequences. The existence of different polypeptide conformers underlies to a variety of disease states, which may be assessed using antibody that is specific for a given conformer. Thus, such antibody thus is useful for identifying or detecting certain conformers within a mixed population of conformers.
Method For Producing Reticulocyte Lysate And Uses Thereof
Method For Producing Reticulocyte Lysate And Uses Thereof
US Patent:
2009015, Jun 18, 2009
Filed:
Dec 12, 2007
Appl. No.:
11/955337
Inventors:
William Hansen - San Francisco CA, US
Vishwanath Lingappa - San Francisco CA, US
Vishwanath Lingappa - San Francisco CA, US
International Classification:
A01N 1/02
US Classification:
435 2
Abstract:
Methods for producing substantially pure porcine reticulocyte lysate are provided. In one embodiment, the methods include inducing a reduction in the hematocrit of a pig to a level of between about 20% and about 25%; extracting at least a portion of blood from the pig; isolating a fraction of the blood containing substantially red blood cells; and preparing a porcine reticulocyte lysate preparation from the isolated fraction.